Andelyn Biosciences will develop and manufacture an AAV9 gene therapy for GM2 gangliosidosis — a group of rare, fatal inherited disorders including Tay-Sachs and Sandhoff diseases — in partnership with Queen’s University.

What the disease does

GM2 gangliosidosis is a lysosomal storage disorder. A missing enzyme allows a fatty substance to accumulate in nerve cells, causing progressive loss of brain and spinal-cord neurons.

The lysosome is the cell’s recycling compartment, breaking down waste molecules. When one enzyme in that system is absent, its substrate accumulates — and because neurons are long-lived and cannot be replaced, they bear the consequences most severely.

In the infantile form, children develop normally for several months and then regress, losing acquired skills before developing seizures, blindness and paralysis. Most die in early childhood. There are no approved disease-modifying treatments for most forms.

Why gene therapy is the logical approach

The genetics are unusually clean. A single missing enzyme causes the disease, and supplying a working copy of the gene should restore function.

Two features make it particularly suited to gene therapy. Only modest enzyme levels are typically needed — carriers with roughly half-normal activity are entirely healthy, so a therapy need not achieve full restoration. And enzymes can be taken up by neighbouring cells, meaning corrected cells can help uncorrected ones nearby.

The obstacle is the brain. The enzyme must be present in the central nervous system, and enzyme replacement therapy delivered into the bloodstream does not cross the blood-brain barrier — which is why that approach, effective in some other lysosomal disorders affecting peripheral organs, fails in the neurological forms.

Why AAV9 specifically

Adeno-associated virus serotypes differ in which tissues they enter, and AAV9 is notable for its ability to cross the blood-brain barrier and transduce cells in the central nervous system after systemic administration.

That property is why AAV9 underpins gene therapies for neurological disease generally — it is the vector that can reach the tissue that matters without requiring direct injection into the brain.

Why the manufacturing partner is the news

A manufacturing agreement is not usually the interesting part of a gene therapy programme. Here it is, because manufacturing is where academic gene therapy programmes most often stall.

Producing AAV to clinical standard is genuinely difficult. Yields are low, the process is sensitive, and a substantial fraction of particles produced are empty capsids containing no genetic material — which must be characterised and controlled because they contribute to immune response without contributing benefit.

Regulators require extensive documentation of identity, purity, potency and consistency, and the analytical methods to demonstrate all of that are specialised. A university laboratory can generate compelling animal data and be entirely unable to produce material a regulator will accept in humans.

Andelyn will use its AAV Curator Platform, a modular manufacturing approach with a dedicated cell line and flexible processes — the point of which is that a validated platform allows a new programme to inherit an established process rather than developing one from scratch.

What the parties said

“Our deep expertise in AAV development and production allows us to support Queen’s University with the scale and quality rigour necessary to bring this life-changing therapy one step closer to reality,” said Andelyn CCO Matt Niloff.

Queen’s University’s Dr Jagdeep Walia said the manufacturer’s track record gives confidence that trial participants “will be receiving the highest quality, safe product.”

That framing is worth noting. In a paediatric trial for a fatal disease, product quality is not an abstraction — participants are children who cannot consent, receiving a permanent intervention, and the acceptable margin for manufacturing variability is essentially zero.

Where it stands

The programme is in preclinical development, with clinical trials planned; Andelyn will oversee a multi-phase development effort.

The realistic timeline from preclinical manufacturing agreement to a treated patient is measured in years, and gene therapy for neurodegenerative disease carries the additional problem of timing: in a rapidly progressive infantile disease, neurons already lost cannot be recovered, so benefit likely depends on treating before substantial damage — which requires diagnosing before symptoms, or very shortly after.

Why newborn screening would change the calculation

The timing problem in this disease points toward a solution that sits outside the therapy itself.

Infantile GM2 gangliosidosis progresses rapidly, and neurons already destroyed cannot be recovered by supplying the missing enzyme afterwards. A therapy given once regression has begun is working against damage that has already occurred, which is why several gene therapies for rapidly progressive paediatric neurological disease have shown benefit only when administered very early.

Newborn screening resolves that by identifying affected infants before symptoms, and screening panels have expanded substantially as treatments have become available for conditions previously only diagnosable after damage was done.

The dependency runs in both directions, which is the awkward part. Screening programmes are generally justified by the existence of an effective treatment, and treatments are difficult to demonstrate without patients identified early enough to benefit. Programmes for conditions like this tend to advance only when both move together.

For fatal paediatric neurodegenerative diseases with no options, reliable manufacturing is frequently the difference between a promising academic programme and one that reaches patients at all. Business and R&D news.